Furthermore, studies have found that the expression of ITGAM impacts AML chemotherapy resistance, and higher expression of ITGAM/CD56 combined with lower expression of Smac/DIABLO's can be an essential predictor of AML chemotherapy resistance [34, 35]. This evidence concerns the gene NCAM1 and acute myeloid leukemia.